Ex-GSK exec named as Chief Medical Officer at Immatics Biotechnologies
Immatics Biotechnologies welcomed former GlaxoSmithKline executive Dr Cedrik Britten to the company as its new Chief Medical Officer (CMO) on 1 June.
Dr Britten has built more than 10 years of experience in clinical and preclinical research, as well as immuno-oncology drug development. He is also a fully trained physician. In his new position, he will hold responsibility for the development and management of Immatics’ product pipeline.
He joins Immatics from GlaxoSmithKline, where he most recently held the role of Vice President and Head of the Oncology Cell Therapy Research Unit.
Meanwhile, the company’s former CMO, Dr Carsten Reinhardt, has moved into the newly created role of Chief Development Officer at the company where he will have oversight and responsibility for Immatics’ product development strategy. This is in addition to his continued leadership of the company’s Immunology and Translational Development functions and TCR Bispecifics platform.
Dr Reinhardt said of the move: “Working together with a clinical leader of Cedrik’s caliber will benefit both the company and, hopefully, also the patients in need of innovative and effective new treatments.”
Immatics’ Chief Executive Officer Dr Harpreet Singh commented on the new appointments: “We are excited about Cedrik joining Immatics. He has an extensive background in cell therapy, translational oncology and immunology as well as great experience in leading clinical and preclinical development programs in immuno-oncology. Cedrik’s appointment enables Carsten to take on the leadership for Immatics’ product development strategy, as Chief Development Officer, as well as retain leadership of the very promising TCR Bispecifics platform and pipeline.”
GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …
GSK and Save the Children have announced that they will be renewing their partnership for …